AXGNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Axogen, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$35.24+0.62 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $1.88B
- P/E (TTM)
- –
- Dividend yield
- –
Axogen, Inc. balance sheet
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 74.6%
- Operating margin
- -5.1%
- Net margin
- -13.4%
- Return on equity, FY2025
- -13.5%
Financial strength
- Current ratio
- 6.60
- Debt to equity
- 0.00
- Debt to assets
- 0.0%
- Cash to current liabilities
- 311.4%
Valuation
- P/E ratio
- –
- Price to sales
- 7.48
- Price to book
- 7.34
- Dividend yield
- –